195 related articles for article (PubMed ID: 29931461)
1. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
[TBL] [Abstract][Full Text] [Related]
4. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
[TBL] [Abstract][Full Text] [Related]
5. Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury.
Phillips EG; Beggs LA; Ye F; Conover CF; Beck DT; Otzel DM; Ghosh P; Bassit ACF; Borst SE; Yarrow JF
PLoS One; 2018; 13(3):e0194440. PubMed ID: 29579075
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
8. Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats.
Peng Y; Langermann S; Kothari P; Liu L; Zhao W; Hu Y; Chen Z; Moraes de Lima Perini M; Li J; Cao J; Guo XE; Chen L; Bauman WA; Qin W
JBMR Plus; 2023 Dec; 7(12):e10825. PubMed ID: 38130761
[TBL] [Abstract][Full Text] [Related]
9. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
Wu J; Cai XH; Qin XX; Liu YX
Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
[TBL] [Abstract][Full Text] [Related]
10. Polydatin administration attenuates the severe sublesional bone loss in mice with chronic spinal cord injury.
Zhan J; Luo D; Zhao B; Chen S; Luan J; Luo J; Hou Y; Hou Y; Xu W; Yan W; Qi J; Li X; Zhang Q; Lin D
Aging (Albany NY); 2022 Nov; 14(21):8856-8875. PubMed ID: 36378815
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
[TBL] [Abstract][Full Text] [Related]
12. Anabolic steroids reduce spinal cord injury-related bone loss in rats associated with increased Wnt signaling.
Sun L; Pan J; Peng Y; Wu Y; Li J; Liu X; Qin Y; Bauman WA; Cardozo C; Zaidi M; Qin W
J Spinal Cord Med; 2013 Nov; 36(6):616-22. PubMed ID: 24090150
[TBL] [Abstract][Full Text] [Related]
13. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
[TBL] [Abstract][Full Text] [Related]
14. Electrical stimulation of hindlimb skeletal muscle has beneficial effects on sublesional bone in a rat model of spinal cord injury.
Zhao W; Peng Y; Hu Y; Guo XE; Li J; Cao J; Pan J; Feng JQ; Cardozo C; Jarvis J; Bauman WA; Qin W
Bone; 2021 Mar; 144():115825. PubMed ID: 33348128
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
16. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model.
Virk MS; Alaee F; Tang H; Ominsky MS; Ke HZ; Lieberman JR
J Bone Joint Surg Am; 2013 Apr; 95(8):694-701. PubMed ID: 23595067
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Examination of Bone Loss in Male Rats After Moderate-Severe Contusion Spinal Cord Injury.
Otzel DM; Conover CF; Ye F; Phillips EG; Bassett T; Wnek RD; Flores M; Catter A; Ghosh P; Balaez A; Petusevsky J; Chen C; Gao Y; Zhang Y; Jiron JM; Bose PK; Borst SE; Wronski TJ; Aguirre JI; Yarrow JF
Calcif Tissue Int; 2019 Jan; 104(1):79-91. PubMed ID: 30218117
[TBL] [Abstract][Full Text] [Related]
19. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis.
Virdi AS; Irish J; Sena K; Liu M; Ke HZ; McNulty MA; Sumner DR
J Bone Joint Surg Am; 2015 Jan; 97(2):133-40. PubMed ID: 25609440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
